Stock Ratings / Health Care / VCEL / insiders

BCRX (78) MESO (60) VIR (31) ALVO (58) ⌘ Pro Terminal →

Vericel Corporation (VCEL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$42.91 +4.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $43.17

Vericel Corporation (VCEL) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $2.20B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $43.17 (+0.61%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCEL)Realized 20D OHLCV Swing Band: ±8.3%

Deterministic 5-Pillar Attribution (67/100 Composite)

🔍 WHY VCEL SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (27% of score)

Altman Z-Score 9.94 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+14/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 9% FCF Margin ($24.7M FCF) & 74.4% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$40.10+0.1% Next Q

Q2 (-2Q)

Grade C+$40.13+6% Next Q

Q3 (-1Q)

Grade C+$42.53+0.9% Next Q

Current

Grade C+$42.91+1.6% Hist 90D α

Trajectory: C (59) → C+ (67)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VCEL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, VCEL faces multiple-compression risk if 133.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 133x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($40.58) or 200D SMA ($38.65) invalidates the momentum regime and cuts Target Base ($44.65) toward Bear Floor ($34.83).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VCEL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 67%NO 33%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

VCEL Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (VCEL)

No recent open-market Form 4 cluster sales or emergency dumps flagged on VCEL. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (VCEL Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.55%⚡ TESTING RESISTANCE

2026-10-30O $43.02H $43.02L $40.01C $42.91VOL 598.7K

RES: $43.47SUP: $40.08SMA50: $40.58SMA200: $38.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VCEL Butterfly Map → + Track VCEL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +16.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCEL)

Health Care Rank #118 of 1016 ⚔️ BCRX vs VCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VCEL vs. BCRX, MESO, VIR, ALVO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vericel Corporation (VCEL) ranks #118 by composite RQD confidence (67/100, grade C+) and #245 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BCRX currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with VCEL at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VCEL ACTIVE Vericel Corporation	C+	67/100	133.0x	74.4%	3.4%	+4.43%	$2.20B	Benchmark Subject
BCRX BioCryst Pharmaceuticals Inc.	B+	78/100	8.3x	—	85.0%	+1.79%	$2.18B	/bcrx-vs-vcel →
MESO Mesoblast Limited	C-	60/100	—	—	—	+17.03%	$2.04B	/meso-vs-vcel →
VIR Vir Biotechnology Inc.	E	31/100	—	96.0%	-35.0%	-1.51%	$2.01B	/vir-vs-vcel →
ALVO Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	/alvo-vs-vcel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000887359

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vericel Corporation (VCEL) reported GAAP revenue of $276.3M (+16.5% vs. FY2024 revenue of $237.2M , and +39.9% cumulative change since FY2023) , GAAP net income of $16.5M, operating cash flow of $51.9M, and free cash flow of $24.7M (+525.9% YoY). On the balance sheet, VCEL closed FY2025 with $488.0M in total assets against $0 in total debt (Altman Z-Score: 9.94, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$276.3M	$16.5M	$51.9M	$24.7M	$488.0M	—
FY2024 (FY)	2024-12-31	$237.2M	$10.4M	$58.2M	-$5.8M	$432.7M	—
FY2023 (FY)	2023-12-31	$197.5M	-$3.2M	$35.3M	$35.3M	—	—

3. VCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Vericel Corporation (NASDAQ: VCEL) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $42.91 (+4.43% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, VCEL ranks #118 in composite RQD confidence.

How does VCEL compare to BCRX and MESO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VCEL carries a Roarable C+ (67/100 RQD), trailing P/E of 133.0x, gross margin of 74.4%, and ROIC of 3.4%. By comparison, BCRX (BioCryst Pharmaceuticals Inc.) holds a B+ grade (78/100 RQD, P/E 8.3x, ROIC 85.0%, cap $2.18B) and MESO (Mesoblast Limited) posts a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $2.04B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VCEL?

Per VCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000887359), Vericel Corporation generated $276.3M in revenue (+16.5% YoY), $16.5M in net income, and $24.7M in free cash flow against $488.0M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

VCEL last traded at $42.91 (+4.43% on volume of 544,850 shares), positioning the stock +5.74% above its 50-day simple moving average ($40.58) and +11.02% above its 200-day simple moving average ($38.65). Across its 52-week range of $28.95 to $49.32, VCEL sits at the 68.5% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±8.3% ($39.35 to $46.47).

VCEL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are VCEL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies VCEL leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: VCEL RQD Cockpit VCEL 12M Forecast VCEL Earnings & Move VCEL Dividends & DRIP VCEL Insiders & 13F VCEL Whale Options VCEL Profit Sankey VCEL News & Why